ImQuest CRO Antiviral Testing Microbicides HIV

Microbicides and STI Prevention Services

Expertise for the Development of Agents to Prevent STIs

For the past decade, ImQuest has been at the forefront of topical microbicide development and discovery research. Our programs assess the activity of agents, defines the mechanism of action of potential microbicides, and quantifies the toxicity of a potential microbicide against cells, tissues and organisms relevant to microbicide product use.

Evaluation of Activity Against Other STI Relevant Organisms

  • HIV
  • HSV-1
  • HSV-2
  • HPV
  • Hepatitis viruses
  • Neisseria gonorrhoeae
  • Chlamydia trachomatis
  • Trichomonas vaginalis
  • Candida albicans
  • Gardnerella vaginalis

Quantification of Anti-Viral Activity and Cellular Toxicity

  • Evaluation of antiviral activity using well-characterized laboratory strains of virus
  • Evaluation against geographically diverse strains
  • Evaluation of antiviral activity in relevant primary cells and tissues
  • Antiviral activity across a range of viral multiplicities of infection
  • Antiviral activity following pH transition from pH 4 to pH 7
  • Protection against infection by cell-free and cell-associated HIV-1 virus
  • Antiviral activity in the presence of whole semen, seminal plasma, cervicovaginal lavage fluid and mucin
  • Virucidal activity evaluations for agents which inactivate infectious virus
  • Evaluation of virus sterilization using the Microbicide Transmission and Sterilization Assay (MTSA)

Determination of Mechanism of Action

  • Inhibition of virus entry to include attachment, fusion and entry through co-receptors
  • Direct virus inactivation (virucidal activity)
  • Inhibition of reverse transcriptase
  • Inhibition of integrase
  • Inhibition of protease

Selection and Characterization of Resistant Virus

  • Assess the susceptibility of approved drugs to microbicide-resistant HIV variants
  • Assess the susceptibility of the microbicide to variants resistant to approved antiretroviral drugs
  • Perform resistant virus selection on microbicide candidates to assess the relative ease of resistant virus selection as well as the genotype and fitness of resistant viruses that emerge during selection

Toxicity to Normal Human Vaginal Microflora and Other Relevant Cell Types

  • Cervical, vaginal and rectal specific cell lines
  • Epivaginal tissue
  • Normal vaginal flora, Lactobacillus including static and cidal activity
ImQuest BioSciences is a preclinical contract research and development organization (CRO) that provides service to evaluate the potential efficacy of new and novel pharmaceutical products for the treatment and prevention of viruses, bacteria, cancer and inflammatory disease, including in vitro toxicology and pharmaceutical product characterization services.